Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Her2+
•
Breast Cancer, Metastatic
How do you approach treatment in a young de novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Related Questions
How would you treat a patient with HER2 positive CNS only progression on fam-trastuzumab which had previously progressed on tucatinib/capecitabine/trastuzumab, and has failed both SRS and WBRT?
Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Can Elacestrant be used in combination with Her 2 targeted therapy in metastatic Triple positive Breast cancer with ESR1 mutation in the second line setting?
In a patient with hormone-positive early breast cancer who experienced a myocardial infarction (MI) while on aromatase inhibitors (AI), should tamoxifen be considered as an alternative treatment?
What are your top takeaways in Breast Cancer from ASCO 2024?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
Do you routinely check echocardiograms on all patients who are starting TDM1?
What strategies do you implement to control the nausea from Enhertu?
Are there scenarios where you would consider use of capivasertib for non-AKT pathway altered patients given the efficacy seen in the overall treatment population of the CAPItello-291 trial?
Do you use breast MRI or ultrasound to assess tumor size prior to neoadjuvant chemotherapy in breast cancer?
